SCHEMBL6296457

SCHEMBL6296457

CC(C)C1(CCc2ccccc2)CC(O)=C(Sc2cc3[nH]c(=O)[nH]c3cc2C(C)(C)C)C(=O)O1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 12/20 0.34
LDHB P07195 4/20 0.33
MLNR O43193 1/20 0.31
NR1I2 O75469 1/20 0.31
ABCB11 O95342 1/20 0.31
PGR P06401 1/20 0.31
CTSD P07339 1/20 0.31
CHRM2 P08172 1/20 0.31
ADRA2A P08913 1/20 0.31
PGA5 P0DJD9 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
CTSE P14091 1/20 0.31
GABRA1 P14867 1/20 0.31
ADRA2C P18825 1/20 0.31
DRD1 P21728 1/20 0.31
HTR2A P28223 1/20 0.31
AGTR1 P30556 1/20 0.31
CCKAR P32238 1/20 0.31
ADRA1A P35348 1/20 0.31
PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302972 0.88 LDHA (0.35) LDHALDHB
SCHEMBL6302969 0.88 LDHA (0.35) LDHALDHB
SCHEMBL6296832 0.87 LDHA (0.33) LDHALDHBMLNRNR1I2ABCB11
SCHEMBL6296833 0.87 LDHA (0.33) LDHALDHBMLNRNR1I2ABCB11
SCHEMBL6303069 0.87 SRD5A2 (0.33) LDHALDHB
SCHEMBL6302985 0.86 LDHA (0.32) LDHALDHBMLNRNR1I2ABCB11
SCHEMBL6302986 0.86 LDHA (0.32) LDHALDHBMLNRNR1I2ABCB11
SCHEMBL6297880 0.83 KDM4E (0.39) LDHASLC6A3
SCHEMBL6296658 0.82
SCHEMBL6296566 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US claimed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US claimed
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD LDHA 1807/4885LDHB 1604/4885MLNR 3321/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD LDHA 1791/4885LDHB 1624/4885MLNR 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.